Diagnosis and management of defects of mitochondrial β-oxidation

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 5, Issue 6, 2002, Pages 601-609

  Vockley, Jerry ^a   Singh, Rani H ^b   Whiteman, David A H ^a  

^a MAYO CLINIC   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

oxidation; Enzyme deficiency; Fatty acid metabolism; Hypoglycemia; Mitochondria; Sudden infant death syndrome

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; CARNITINE; DOCOSAHEXAENOIC ACID; GLUCOSE; HEPTANOIC ACID DERIVATIVE; KETONE BODY; MULTIVITAMIN; RIBOFLAVIN; STARCH; FATTY ACID;

DIAGNOSTIC TEST; DIET SUPPLEMENTATION; DIET THERAPY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EARLY DIAGNOSIS; ENERGY METABOLISM; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; HEART ARRHYTHMIA; HUMAN; INHERITANCE; NEWBORN SCREENING; PREGNANCY; REVIEW; SYMPTOMATOLOGY; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; ENZYMOLOGY; INBORN ERROR OF METABOLISM; METABOLISM; MITOCHONDRION; OXIDATION REDUCTION REACTION;

FATTY ACIDS; HUMANS; LIPID METABOLISM, INBORN ERRORS; METABOLISM, INBORN ERRORS; MITOCHONDRIA; OXIDATION-REDUCTION;

EID: 0141581015     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-200211000-00002     Document Type: Review

References (103)

1. Roe CR, Ding J. Mitochondrial fatty acid oxidation disorders. In: Scriver C, Beaudet AL, Sly W, et al., editors. The metabolic and molecular basis of inherited disease. 8th ed. New York: McGraw-Hill; 2001. pp. 2297-2326. A standard reference chapter on the molecular basis of and clinical symptoms in inborn errors of β-oxidation.
2. Wanders RJA. Single peroxisomal enzyme deficiencies. In: Scriver C, Beaudet AL, Sly W, et al., editors. The metabolic and molecular basis of inherited disease. 8th ed. New York: McGraw-Hill; 2001. pp. 3219-3256.
3. Saudubray JM, Martin D, de Lonlay P, et al. Recognition and management of fatty acid oxidation defects: a series of 107 patients. J Inherit Metab Dis 1999; 22:488-502.
4. Bennett M, Rinaldo P, Strauss A. Inborn errors of mitochondrial fatty acid oxidation. Grit Rev Clin Lab Sci 2000; 37:1-44.
5. Engel AG, Angelini C. Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy: a new syndrome. Science 1973; 173:899-902.
6. DiMauro S, DiMauro PMM. Muscle carnitine palmitoyl transferase deficiency and myoglobinuria. Science 1973; 182:929-931.
7. Vockley J. The changing face of disorders of fatty acid oxidation. Mayo Clin Proc 1994; 69:249-257.
8. Rinaldo P, Raymond K, Al-Odaib A, et al. Clinical and biochemical features of fatty acid oxidation disorders. Curr Opin Pediatr 1998; 10:615-621.
9. Wanders RJA, Vreken P, Den Boer MEJ, et al. Disorders of mitochondrial fatty acyl-CoA β-oxidation. J Inherit Metab Dis 1999; 22:442-487.
10. Matsubara Y, Indo Y, Naito E, et al. Molecular cloning and nucleotide sequence of cDNAs encoding the precursors of rat long chain acyl-CoA, short chain acyl-CoA, and isovaleryl CoA dehydrogenases: sequence homology of four enzymes of the acyl-CoA dehydrogenase family. J Biol Chem 1989; 264:16321-16331.
11. Tanaka K, Matsubara Y, Indo Y, et al. The acyl-CoA dehydrogenase family: homology and divergence of primary sequence of four acyl-CoA dehydrogenases and consideration of their functional significance. In: Tanaka K, Coates PM, editors. Fatty acid oxidation: clinical, biochemical and molecular aspects. New York: Alan R. Liss Inc.; 1990. pp. 577-598.
12. Barycki JJ, O'Brien LK, Bratt JM, et al. Biochemical characterization and crystal structure determination of human heart short chain L-3-hydroxyacyl-CoA dehydrogenase provide insights into catalytic mechanism. Biochemistry 1999; 38:5786-5798.
13. Barycki JJ, O'Brien LK, Birktoft JJ, et al. Pig heart short chain L-3-hydroxyacyl-CoA dehydrogenase revisited. Protein Sci 1999; 8:2010-2018.
14. Vredendaal P, Vandenberg IET, Malingre HEM, et al. Human short-chain L-3-hydroxyacyl-CoA dehydrogenase: cloning and characterization of the coding sequence. Biochem Biophys Res Commun 1996; 223:718-723.
15. Kamijo T, Indo Y, Souri M, et al. Medium chain 3-ketoacyl-coenzyme A thiolase deficiency: a new disorder of mitochondrial fatty acid beta-oxidation. Pediatr Res 1997; 42:569-576.
16. Bennett MJ, Sherwood WG. 3-Hydroxydicarboxylic and 3-ketodicarboxylic aciduria in 3 patients: evidence for a new defect in fatty acid oxidation at the level of 3-ketoacyl-CoA thiolase. Clin Chem 1993; 39:897-901.
17. Bennett MJ, Weinberger MJ, Kobori JA, et al. Mitochondrial short-chain L-3-hydroxyacyl-coenzyme A dehydrogenase deficiency: a new defect of fatty acid oxidation. Pediatr Res 1996; 39:185-188.
18. Helander HM, Koivuranta KT, Horellikuitunen N, et al. Molecular cloning and characterization of the human mitochondrial 2,4-dienoyl-CoA reductase gene. Genomics 1997; 46:112-119.
19. Lea WP, Abbas AS, Sprecher H, et al. Long-chain acyl-CoA dehydrogenase is a key enzyme in the mitochondrial beta-oxidation of unsaturated fatty acids. Biochim Biophys Acta Mol Cell Biol Lipids 2000; 31:2-3.
20. Fukao T, Song XQ, Mitchell GA, et al. Enzymes of ketone body utilization in human tissues: protein and messenger RNA levels of succinyl-coenzyme A (CoA)-3-ketoacid CoA transferase and mitochondrial and cytosolic acetoacetyl-CoA thiolases. Pediatr Res 1997; 42:498-502.
21. Thompson GN, Hsu BYL, Pitt JJ, et al. Fasting hypoketotic coma in a child with deficiency of mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. N Engl J Med 1997; 337:1203-1207.
22. Mitchell GA, Fukao T. Inborn errors of ketone body metabolism. In: Scriver C, Beaudet AL, Sly W, et al., editors. The metabolic and molecular basis of inherited disease. 8th ed. New York: McGraw-Hill; 2001. pp. 2327-2356. A standard textbook reference for these disorders.
23. Al Odaib A, Shneider BL, Bennett MJ, et al. A defect in the transport of long-chain fatty acids associated with acute liver failure. N Engl J Med 1998; 339:1752-1757.
24. Lamhonwah AM, Tein I. Carnitine uptake defect: frameshift mutations in the human plasmalemmal carnitine transport gene. Biochem Biophys Res Commun 1998; 252:396-401.
25. Nezu JI, Tamai I, Oku A, et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet 1999; 21:91-94.
26. Lamhonwah AM, Tein I. GFP-human high-affinity carnitine transporter OCTN2 protein: subcellular localization and functional restoration of carnitine uptake in mutant cell lines with the carnitine transporter defect. Biochem Biophys Res Commun 1999; 264:909-914.
27. Demaugre F, Bonnefont J-P, Mitchell G, et al. Hepatic and muscular presentations of carnitine palmitoyl transferase deficiency: two distinct entities. Pediatr Res 1988; 24:308-311.
28. Demaugre G, Bonnefont J-P, Cepanec C, et al. Immunoquantitative analysis of human carnitine palmitoyltransferase I and II defects. Pediatr Res 1990; 27:497-500.
29. Hug G, Bove KE, Soukup S. Lethal neonatal multiorgan deficiency of carnitine palmitoyltransferase II. N Engl J Med 1991; 325:1862-1864.
30. Stanley CA, Sunaryo F, Hale DE, et al. Elevated plasma carnitine in the hepatic form of carnitine palmitoyltransferase-1 deficiency. J Inherit Metab Dis 1992; 15:785-789.
31. Vianey-Saban C, Mousson B, Bertrand C, et al. Carnitine palmitoyl transferase-1 deficiency presenting as a Reye-like syndrome without hypoglycaemia. Eur J Pediatr 1993; 152:334-338.
32. Britton CH, Schultz RA, Zhang B, et al. Human liver mitochondrial carnitine palmitoyltransferase. I: Characterization of its cDNA and chromosomal localization and partial analysis of the gene. Proc Natl Acad Sci USA 1995; 92:1984-1988.
33. Ijlst L, Mandel H, Oostheim W, et al. Molecular basis of hepatic carnitine palmitoyltransferase I deficiency. J Clin Invest 1998; 102:527-531.
34. Lopriore E, Gemke R, Verhoeven NM, et al. Carnitine-acylcarnitine translocase deficiency: phenotype, residual enzyme activity and outcome. Eur J Pediatr 2001; 160:101-104. Surveyed outcomes in 21 patients and concluded that phenotype and residual enzyme activity do not appear to be major prognostic factors.
35. Bonnet D, Martin D, de Lonlay P, et al. Arrhythmias and conduction defects as presenting symptoms of fatty add oxidation disorders in children. Circulation 1999; 100:2248-2253.
36. Parini R, Invernizzi F, Menni F, et al. Medium-chain triglyceride loading test in carnitine-acylcarnitine translocase deficiency: insights on treatment. J Inherit Metab Dis 1999; 22:733-739.
37. Roschinger W, Muntau A, Duran M, et al. Carnitine-acylcarnitine translocase deficiency: metabolic consequences of an impaired mitochondrial carnitine cycle. Clin Chim Acta 2000; 298:55-68.
38. Taroni F, Verderio E, Fiorucci S, et al. Molecular characterization of inherited carnitine palmitoyltransferase II deficiency. Proc Natl Acad Sci USA 1992; 89:8429-8433.
39. Taroni F, Verderio E, Dworzak F, et al. Identification of a common mutation in the carnitine palmitoyltransferase II gene in familial recurrent myoglobinuria patients. Nat Genet 1993; 4:314-320.
40. Bonnefont JP, Taroni F, Cavadini P, et al. Molecular analysis of carnitine palmitoyltransferase II deficiency with hepatocardiomuscular expression. Am J Hum Genet 1996; 58:971-978.
41. Elpeleg ON, Joseph A, Gutman A. Profound carnitine palmitoyltransferase II deficiency: reply. J Pediatr 1994; 124:160-161.
42. Aoyama T, Souri M, Ushikubo S, et al. Purification of human very-long-chain acyl-coenzyme A dehydrogenase and characterization of its deficiency in seven patients. J Clin Invest 1995; 95:2465-2473.
43. Yamaguchi S, Indo Y, Coates PM, et al. Identification of very-long-chain acyl-CoA dehydrogenase deficiency in three patients previously diagnosed with long-chain acyl-CoA dehydrogenase deficiency. Pediatr Res 1993; 34:111-113.
44. Matsubara Y, Narisawa K, Shigeaki M, et al. Identification of a common mutation in patients with medium-chain acyl-CoA dehydrogenase deficiency. Biochem Biophys Res Commun 1990; 171:498-505.
45. Andresen BS, Brass P, Udvari S, et al. The molecular basis of medium-chain acyl-coA dehydrogenase (MCAD) deficiency in compound heterozygous patients: is there correlation between genotype and phenotype? Hum Mol Genet 1997; 6:695-707.
46. Gregersen N, Andresen BS, Bross P. Prevalent mutations in fatty acid oxidation disorders: diagnostic considerations. Eur J Pediatr 2000; 159:3213-3218.
47. Andresen B, Dobrowolski S, O'Reilly L, et al. Medium-chain acyl-coA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. Am J Hum Genet 2001; 68:1408-1418. Found a frequency of 1:15000 babies in the US through newborn screening by tandem mass spectroscopy.
48. Chace DH, Adam BW, Smith SJ, et al. Validation of accuracy-based amino acid reference materials in dried blood spots by tandem mass spectrometry for newborn screening assays. Clin Chem 1999; 45:1269-1277.
49. Green A, Pollitt RJ. Population newborn screening for inherited metabolic disease. J Inherit Metab Dis 1999; 22:572-579.
50. Ciske JB, Hoffman G, Hanson K, et al. Newborn screening in Wisconsin: program overview and test addition. WMJ 2000; 99:38-42.
51. Chace DH, DiPerna JC, Naylor EW. Laboratory integration and utilization of tandem mass spectrometry. Acta Paediatr Suppl 1999; 88:45-47.
52. Amendt B, Green C, Sweetman L, et al. Short chain acyl-CoA dehydrogenase deficiency: clinical and biochemical studies in two patients. J Clin Invest 1987; 79:1303-1309.
53. Coates PM, Hale DE, Finocchiaro G, et al. Genetic deficiency of short chain acyl-CoA dehydrogenase in cultured fibroblasts from a patient with muscle carnitine deficiency and severe skeletal muscle weakness. J Clin Invest 1988; 81:171-175.
54. Bhala A, Willi SM, Rinaldo P, et al. Clinical and biochemical characterization of short-chain acyl-coenzyme A dehydrogenase deficiency. J Pediatr 1995; 126:910-915.
55. Sewell AC, Herwig J, Bohles H, et al. A new case of short chain acyl-CoA dehydrogenase deficiency with isolated ethylmalonic aciduria. Eur J Pediatr 1993; 152:922-924.
56. Turnbull DM, Bartlett K, Stevens DL, et al. Short-chain acyl-CoA dehydrogenase deficiency associated with a lipid-storage myopathy and secondary carnitine deficiency. N Engl J Med 1984; 311:1232-1236.
57. Gregersen N, Winter VS, Corydon MJ, et al. Identification of four new mutations in the short-chain acyl-CoA dehydrogenase (SCAD) gene in two patients: one of the variant alleles, 511C→T, is present at an unexpectedly high frequency in the general population, as was the case for 625G→A, together conferring susceptibility to ethylmalonic aciduria. Hum Mol Genet 1998; 7:619-627.
58. Tein I, Haslam RHA, Rhead WJ, et al. Short-chain acyl-CoA dehydrogenase deficiency: a cause of ophthalmoplegia and multicore myopathy. Neurology 1999; 52:366-372.
59. Corydon M, Vockley J, Rinaldo R, et al. Role of common gene variations in the molecular pathogenesis of short-chain acyl-CoA dehydrogenase deficiency. Pediatr Res 2001; 49:18-23. This paper demonstrated the difficulty of differentiating between causative mutations, benign variants and disease susceptibility alleles in this disease.
60. Kristensen MJ, Kmoch S, Bross P, et al. Amino acid polymorphism (Gly209Ser) in the ACADS gene. Hum Mol Genet 1994; 3:1711.
61. Corydon MJ, Gregersen N, Lehnert W, et al. Ethylmalonic aciduria is associated with an amino acid variant of short chain acyl-coenzyme A dehydrogenase. Pediatr Res 1996; 39:1059-1066.
62. Frerman F, Goodman S. Defects of electron transfer flavoprotein and electron transfer flavoprotein-ubiquinone oxidoreductase: glutaric acidemia type II. In: Scriver C, Beaudet AL, Sly W, et al., editors. The metabolic and molecular basis of inherited disease. 8th ed. New York: McGraw-Hill; 2001. pp. 2357-2365. A standard text reference for this disorder.
63. Takanashi J, Fujii K, Sugita K, et al. Neuroradiologic findings in glutaric aciduria type II. Pediatr Neural 1999; 20:142-145.
64. Stockler S, Radner H, Karpf EF, et al. Symmetric hypoplasia of the temporal cerebral lobes in an infant with glutaric aciduria type II (multiple acyl-coenzyme A dehydrogenase deficiency). J Pediatr 1994; 124:601-604.
65. Miyajima H, Orii KE, Shindo Y, et al. Mitochondrial trifunctional protein deficiency associated with recurrent myoglobinuria in adolescence. Neurology 1997; 49:833-837.
66. Fukao T, Yamaguchi S, Orii T, et al. Molecular basis of beta-ketothiolase deficiency: mutations and polymorphisms in the human mitochondrial acetoacetyl-coenzyme A thiolase gene. Hum Mutat 1995; 5:113-120.
67. Fukao T, Song XQ, Yamaguchi S, et al. Identification of three novel frameshift mutations (83delAT, 754insCT, and 435+1G to A) of mitochondrial acetoacetyl-coenzyme A thiolase gene in two Swiss patients with CRM-negative beta-ketothiolase deficiency. Hum Mutat 1997; 9:277-279.
68. Roe CR, Millington DS, Kodo NN, et al. 2,4-Dienoyl-coenzyme A reductase deficiency: a possible new disorder of fatty acid oxidation. J Clin Invest 1990; 85:1703-1707.
69. Kassovskabratinova S, Fukao T, Song XQ, et al. Succinyl CoA-3-oxoacid CoA transferase (SCOT): human cDNA cloning, human chromosomal mapping to 5p13, and mutation detection in a SCOT-deficient patient. Am J Hum Genet 1996; 59:519-528.
70. Song XQ, Fukao T, Mitchell GA, et al. Succinyl-CoA-3-ketoacid coenzyme A transferase (SCOT): development of an antibody to human SCOT and diagnostic use in hereditary SCOT deficiency. BBA Mol Basis Dis 1997; 1360:151-156.
71. Pretorius CJ, Son GGL, Bonnici F, et al. Two siblings with episodic ketoacidosis and decreased activity of succinyl-CoA-3-ketoacid CoA-transferase in cultured fibroblasts. J Inherit Metab Dis 1996; 19:296-300.
72. Vockley J, Rinaldo P, Bennett MJ, et al. Synergistic heterozygosity: disease resulting from multiple partial defects in one or more metabolic pathways. Mol Genet Metab 2000; 71:10-18.
73. Vladutiu G. Complex phenotypes in metabolic muscle diseases. Muscle Nerve 2000; 23:1157-1159.
74. Ibdah JA, Bennett MJ, Rinaldo P, et al. A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. N Engl J Med 1999; 340:1723-1731.
75. Ibdah JA, Dasouki MJ, Strauss AW. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: variable expressivity of maternal illness during pregnancy and unusual presentation with infantile cholestasis and hypocalcaemia. J Inherit Metab Dis 1999; 22:811-814.
76. Matern D, Hart P, Murtha A, et al. Acute fatty liver of pregnancy associated with short-chain acyl-coenzyme A dehydrogenase deficiency. J Pediatr 2001; 138:585-588. Widens the scope of the disorders in which this problem occurs.
77. Chalmers RA, Stanley CA, English N, et al. Mitochondrial carnitine-acylcarnitine translocase deficiency presenting as sudden neonatal death. J Pediatr 1997; 131:220-225.
78. Bonnefont JP, Haas R, Wolff J, et al. Deficiency of carnitine palmitoyltransferase I. J Child Neurol 1989; 4:198-203.
79. Innes AM, Seargeant LE, Balachandra K, et al. Hepatic carnitine palmitoyltransferase I deficiency presenting as maternal illness in pregnancy. Pediatr Res 2000; 47:43-45.
80. Nelson J, Lewis B, Walters B. The HELLP syndrome associated with fetal medium-chain acyl-CoA dehydrogenase deficiency. J Inherit Metab Dis 2000; 23:18-19.
81. Walter JH. Inborn errors of metabolism and pregnancy. J Inherit Metab Dis 2000; 23:229-236.
82. Saudubray J-M, Mitchell G, Bonnefornt J-P, et al. Approach to the patient with a fatty acid oxidation disorder. In: Coates PM, Tanaka K, editors. Progress in clinical and biological research: new developments in fatty acid oxidation. New York: Wiley-Liss; 1992. pp. 271-288.
83. Ziadeh R, Hoffman EP, Finegold DN, et al. Medium chain acyl-CoA dehydrogenase deficiency in Pennsylvania: neonatal screening shows high incidence and unexpected mutation frequencies. Pediatr Res 1995; 37:675-678.
84. Carpenter KH, Wilcken B. Neonatal diagnosis of long-chain 3-hydroxyacyl-CoA dehydrogenase. J Inherit Metab Dis 1999; 22:840-841.
85. Wilson CJ, Champion MP, Collins JE, et al. Outcome of medium chain acyl-CoA dehydrogenase deficiency after diagnosis. Arch Dis Child 1999; 80:459-462.
86. Wiley V, Carpenter K, Wilcken B. Newborn screening with tandem mass spectrometry: 12 months' experience in NSW Australia. Acta Paediatr Suppl 1999; 88:48-51.
87. Schmidt-Sommerfeld E, Penn D, Kerner J, et al. Quantitation of urinary carnitine esters in a patient with medium-chain acyl-coenzyme A dehydrogenase deficiency, effect of metabolic state and L-carnitine therapy. J Pediatr 1989; 115:577-582.
88. Tream WR, Stanley CA, Goodman SI. Medium chain acyl-CoA dehydrogenase deficiency: metabolic effects and therapeutic efficacy of long-term L-carnitine supplementation. J Inherit Metab Dis 1989; 12:112-119.
89. Catzeflis C, Bachmann C, Hale DE, et al. Early diagnosis and treatment of neonatal medium-chain acyl-CoA dehydrogenase deficiency: report of two siblings. Eur J Pediatr 1990; 149:577-581.
90. Sous J, Singh R. Management of fatty oxidation disorders: a survey of current recommendations. J Am Diet Assoc, in press.
91. Kerner J, Hoppel C. Genetic disorders of carnitine metabolism and their nutritional management. Annu Rev Nutr 1998; 18:179-206.
92. Fernandes J, Smit G. The glycogen storage diseases. In: Fernandes J, Saudubray J, Van den Berghe C, editors. Inborn error of metabolic diseases, diagnosis and treatment. 3rd ed. New York: Springer; 2001. pp. 88-101.
93. Viol CD, Burlina AB, Bertini E, et al. Progressive neuropathy and recurrent myoglobinuria in a child with long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. J Pediatr 1991; 118:744-746.
94. Hayde M, Widhalm K. Effects of cornstarch treatment in very young children with type I glycogen storage disease. Eur J Pediatr 1990; 149:630-633.
95. Howat AJ, Bennett MJ, Variend S, et al. Defects of metabolism of fatty acids in the sudden infant death syndrome 1985; 290:1771-1773.
96. Rinaldo P, Schmidtsommerfeld E, Posca AP, et al. Effect of treatment with glycine and L-carnitine in medium-chain acyl-coenzyme-A dehydrogenase deficiency. J Pediatr 1993; 122:580-584.
97. Nyhan W, Ozand P. Disorders of fatty acid oxidation. In: Atlas of metabolic diseases. 1st ed. London, UK: Chapman & Hall Medical; 1998, pp. 223-230.
98. Pollitt RJ. Disorders of mitochondrial long-chain fatty acid oxidation. J Inherit Metab Dis 1995; 18:473-490.
99. Gillingham M, Van Calcar S, Ney D, et al. Dietary management of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD): a case report and survey. J Inherit Metab Dis 1999; 22:123-131.
100. Uauy R, Treen M, Hoffman DR. Essential fatty acid metabolism and requirements during development. Semin Perinatol 1989; 13:118-130.
101. Harding CO, Gillingham MB, van Calcar SC, et al. Docosahexaenoic acid and retinal function in children with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. J Inherit Metab Dis 1999; 22:276-280.
102. Roe CR, Sweetman L, Roe DS, et al. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest 2002; 110:259-269. Proposes depletion of the tricarboxylic acid cycle intermediates as a primary cause of pathogeneis in long chain fat metabolism defects and a new therapy based on this hypothesis.
103. Acosta P, Yannicelli S. The Ross Metabolic Formula System Nutrition Support Protocols. Columbus, OH: Ross Products Divisions; 2001.